A phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients with either differentiated or medullary thyroid cancer progressing after first line t...
Full Title: A phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients with either differentiated or medullary thyroid cancer progressing after first line t...
The study evaluates nintedanib, a multi‑target tyrosine‑kinase inhibitor, as second‑line therapy in differentiated and medullary thyroid cancer, conditions with limited options after first‑line treatment failures, potentially providing new evidence for disease management.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- The dual axis of tumorigenesis: MAPK and PI3K/AKT pathways in papillary thyroid carcinoma
- The molecular mechanisms and potential therapeutic implications of the crosstalk between DNA methylation and metabolic reprogramming in thyroid cancer
- Improving predicted risk of recurrence using molecular profiling in papillary thyroid cancer
- Global Burden of Thyroid Cancer in Adults Age 15‑49 Years and Its Predictions: Findings From Global Burden of Disease Study 2021
- Thyroid Cancer: Pathogenesis, Clinicopathology, Diagnosis, and Management